DNA Related Topics 
Drug Discovery World
JANUARY 23, 2024
” The ability to collect and analyse such a new wealth of ocean data comes from major developments in DNA sequencing technology and computational power. The post World’s largest catalogue of ocean DNA could boost drug discovery appeared first on Drug Discovery World (DDW).
Drug Discovery World
NOVEMBER 20, 2023
Raquel Sanches-Kuiper , Vice President of Science and Applications at Evonetix, and Clare Whitewoods , Marketing Communications Manager at Evonetix, look at the benefits synthetic DNA brings to pharmaceutical development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
DECEMBER 4, 2023
A novel DNA vaccine in combination with chemotherapy has demonstrated promising clinical results against a deadly form of ovarian cancer. The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1.
Drug Discovery World
MAY 11, 2023
The first DNA synthesised using Evonetix’s semiconductor chip technology has been delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. The DNA was delivered to Dr Jenny Molloy, Co-chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge.
Drug Discovery World
MAY 24, 2023
Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK. The expanded facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year.
Chemical Biology and Drug Design
JANUARY 29, 2024
MGMT mRNA expression was significantly increased in CD138+ myeloma cells compared with their matched CD138-nontumorigenic cells and inhibition of MGMT by its specific inhibitor lomeguatrib in MM cells reduced DNA repair, cell viability, and S phase entry and increased DNA damage and apoptosis.
Drug Discovery World
AUGUST 16, 2023
Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. Many scientists are now discovering that this junk DNA plays an essential role in our biology and the epigenetic processes that respond to the environment to drive disease.
Expert insights. Personalized for you.
258 
Let's personalize your content